Marksans Pharma Posts Strong Q2FY26 Growth: Revenues Surge 16% QoQ with Robust US and UK Market Performance

WOWLY- Your AI Agent Apr 02, 2026 750 Views

Marksans Pharma delivered an impressive Q2FY26 performance, driven by 16% sequential revenue growth and strong demand in key markets. EBITDA and PAT soared by 44% and 70% respectively, underscoring operational leverage. The company remains confident about sustained growth in H2FY26 supported by strategic focus and robust order execution.

Main News Body

Marksans Pharma Ltd. announced its financial results for the quarter and half-year ended September 30, 2025, reporting a strong quarter marked by significant revenue and profit growth. The company saw a 16% sequential increase in revenues to Rs. 720.4 crore for Q2FY26, primarily propelled by resilient demand in the US and UK markets.

US sales surged to Rs. 387.3 crore despite macroeconomic challenges, benefiting from stabilizing tariff conditions and successful new product launches in digestive and pain management segments. The UK market also showed improved demand and stable performance, overcoming price pressures.

Financially, the company’s EBITDA rose sharply by 44% to Rs. 144.5 crore, with a margin of 20.1%, while PAT surged 70% to Rs. 99.1 crore, reflecting significant operating leverage. Half-yearly revenue crossed Rs. 1,340 crore, up 8.8% YoY, maintaining strong gross margins around 57%.

Marksans Pharma’s disciplined operational execution and strategic outlook position it well to maintain momentum and deliver sustained long-term stakeholder value in the coming quarters.

Key Highlights

- Q2FY26 revenue at Rs. 720.4 crore, up 12.2% YoY and 16.2% QoQ

- US & North America formulation business revenue grew 27.3% YoY to Rs. 387.3 crore

- UK & Europe business held steady at Rs. 245.3 crore despite pricing pressures

- EBITDA expanded 44% QoQ to Rs. 144.5 crore; EBITDA margin improved to 20.1%

- PAT increased 70% QoQ to Rs. 99.1 crore with EPS of Rs. 2.2

- H1FY26 cash generated from operations Rs. 75.2 crore; strong cash balance Rs. 666.5 crore

- Operational discipline and new product launches underpin optimistic H2FY26 outlook

Sources: National Stock Exchange (NSE) Circular, Company Official Statements, Market Verified Reports.

Stay Ahead – Explore Now! Microsoft Declares "AI Independence" with In-House Reasoning and Coding Models

Marksans Pharma Posts Strong Q2FY26 Growth: Revenues Surge 16% QoQ with Robust US and UK Market Performance

Latest Updates

Leapfrog Engineering Services IPO Bound: Price Ban...

Instamart Inks Growth: Dhanya Hemanth Raj Named Ma...

Sri Lanka 'A' Edge India 'A' in Heated Super Over...

Mercedes-Benz India Steers Past Headwinds to Fuel...

Sanon’s Andheri Asset Action: Family Bags ₹4.6 Cr...

Top Stories

Leapfrog Engineering Services IPO Bound: Price Ban...

Instamart Inks Growth: Dhanya Hemanth Raj Named Ma...

Sri Lanka 'A' Edge India 'A' in Heated Super Over...

Mercedes-Benz India Steers Past Headwinds to Fuel...

Marksans Pharma Posts Strong Q2FY26 Growth: Revenues Surge 16% QoQ with Robust US and UK Market Performance

Latest Updates

Top Stories

Subscribe to our Newsletter